UMass Amherst researchers have developed a groundbreaking nanoparticle-based cancer vaccine that prevented melanoma, pancreatic, and triple-negative breast cancers in mice—with up to 88% remaining tumor-free. The vaccine triggers a multi-pathway immune response, producing powerful T-cell activation and long-term immune memory that stops both tumor growth and metastasis. By combining cancer-specific antigens with a lipid nanoparticle “super adjuvant,” it overcomes key challenges in cancer immunot
UMass Amherst researchers have developed a groundbreaking nanoparticle-based cancer vaccine that prevented melanoma, pancreatic, and triple-negative breast cancers in mice—with up to 88% remaining tumor-free. The vaccine triggers a multi-pathway immune response, producing powerful T-cell activation and long-term immune memory that stops both tumor growth and metastasis. By combining cancer-specific antigens with a lipid nanoparticle “super adjuvant,” it overcomes key challenges in cancer immunotherapy.
Vast amounts of valuable research data remain unused, trapped in labs or lost to time. Frontiers aims to change that with FAIR² Data Management, a groundbreaking AI-driven system that makes datasets reusable, verifiable, and citable. By uniting curation, compliance, peer review, and interactive visualization in one platform, FAIR² empowers scientists to share their work responsibly and gain recognition.
Vast amounts of valuable research data remain unused, trapped in labs or lost to time. Frontiers aims to change that with FAIR² Data Management, a groundbreaking AI-driven system that makes datasets reusable, verifiable, and citable. By uniting curation, compliance, peer review, and interactive visualization in one platform, FAIR² empowers scientists to share their work responsibly and gain recognition.
Amid the turbulence of the wider global economy in recent years, the pharmaceuticals industry is weathering its own storms. The rising cost of raw materials and supply chain disruptions are squeezing margins as pharma companies face intense pressure—including from countries like the US—to control drug costs. At the same time, a wave of expiring patents threatens around $300 billion in potential lost sales by 2030. As companies lose the exclusive right to sell the drugs they have developed, compe
Amid the turbulence of the wider global economy in recent years, the pharmaceuticals industry is weathering its own storms. The rising cost of raw materials and supply chain disruptions are squeezing margins as pharma companies face intense pressure—including from countries like the US—to control drug costs. At the same time, a wave of expiring patents threatens around $300 billion in potential lost sales by 2030. As companies lose the exclusive right to sell the drugs they have developed, competitors can enter the market with generic and biosimilar lower-cost alternatives, leading to a sharp decline in branded drug sales—a “patent cliff.” Simultaneously, the cost of bringing new drugs to market is climbing. McKinsey estimatescost per launch is growing 8% each year, reaching $4 billion in 2022.
In clinics and health-care facilities, norms and expectations are evolving, too. Patients and health-care providers are seeking more personalized services, leading to greater demand for precision drugs and targeted therapies. While proving effective for patients, the complexity of formulating and producing these drugs makes them expensive and restricts their sale to a smaller customer base.
The need for personalization extends to sales and marketing operations too as pharma companies are increasingly needing to compete for the attention of health-care professionals (HCPs). Estimates suggestthat biopharmas were able to reach 45% of HCPs in 2024, down from 60% in 2022. Personalization, real-time communication channels, and relevant content offer a way of building trust and reaching HCPs in an increasingly competitive market. But with ever-growing volumes of contentrequiring medical, legal, and regulatory (MLR) review, companies are struggling to keep up, leading to potential delays and missed opportunities.
This content was produced by Insights, the custom content arm of MIT Technology Review. It was not written by MIT Technology Review’s editorial staff. It was researched, designed, and written by human writers, editors, analysts, and illustrators. AI tools that may have been used were limited to secondary production processes that passed thorough human review.
Front Med (Lausanne). 2025 Sep 26;12:1648612. doi: 10.3389/fmed.2025.1648612. eCollection 2025.ABSTRACTSmall airways-defined as bronchioles <2 mm in internal diameter that lack cartilaginous support-are frequently involved in the earliest stages of chronic obstructive pulmonary disease (COPD). While COPD is defined per GOLD by persistent post-bronchodilator airflow limitation, small-airway dysfunction can precede spirometric abnormality, motivating earlier, imaging- and physiology-based detec
Front Med (Lausanne). 2025 Sep 26;12:1648612. doi: 10.3389/fmed.2025.1648612. eCollection 2025.
ABSTRACT
Small airways-defined as bronchioles <2 mm in internal diameter that lack cartilaginous support-are frequently involved in the earliest stages of chronic obstructive pulmonary disease (COPD). While COPD is defined per GOLD by persistent post-bronchodilator airflow limitation, small-airway dysfunction can precede spirometric abnormality, motivating earlier, imaging- and physiology-based detection (Agustí et al., 2023). Pathological progression typically begins with loss and stenosis of terminal bronchioles, followed by mucus retention/plugging, fibrotic remodeling, chronic inflammation, microvascular abnormalities, and cellular senescence, ultimately resulting in irreversible impairment of gas exchange. Early diagnosis remains difficult, but a suite of advanced non-invasive modalities-including impulse oscillometry system/forced oscillation techniques (IOS/FOT), single- and multiple-breath washout tests, high-resolution CT with parametric response mapping (PRM), nuclear medicine approaches (e.g., SPECT), dynamic measurements of lung compliance, and Fluorine-19 (19F) MRI-combined with artificial intelligence markedly improve the sensitivity and specificity for detecting small-airway disease. Therapeutic strategies that target cellular senescence and fibrotic pathways-such as senolytics and antifibrotic interventions-are showing promise, particularly approaches that clear senescent cells or block pro-fibrotic signaling. The integration of single-cell omics, high-resolution microvascular imaging, and molecularly targeted therapies is expected to accelerate precision diagnostics and enable personalized early interventions. This review summarizes recent insights into small-airway physiology, key pathophysiological and molecular mechanisms, and current pharmacological strategies, and emphasizes the clinical principle of "early detection, early diagnosis, early intervention" for managing COPD-related small-airway disease.
Nature Biotechnology, Published online: 13 October 2025; doi:10.1038/s41587-025-02854-yDIAL designs synthetic promoters for generation of heritable setpoints of gene expression across a range of cell types.
Nature, Published online: 13 October 2025; doi:10.1038/d41586-025-03135-zA run-in with some artefact-laden AI-generated analyses convinced Lei Zhu that machine learning wasn’t making his role irrelevant, but more important than ever.
A run-in with some artefact-laden AI-generated analyses convinced Lei Zhu that machine learning wasn’t making his role irrelevant, but more important than ever.
Login
